Myriad Genetics, Inc. (MYGN)
Automate Your Wheel Strategy on MYGN
With Tiblio's Option Bot, you can configure your own wheel strategy including MYGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MYGN
- Rev/Share 9.0605
- Book/Share 8.0495
- PB 0.5168
- Debt/Equity 0.1956
- CurrentRatio 1.9002
- ROIC -0.1225
- MktCap 383457984.0
- FreeCF/Share -1.1804
- PFCF -3.5737
- PE -3.2599
- Debt/Assets 0.1323
- DivYield 0
- ROE -0.1539
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MYGN | Scotiabank | Sector Outperform | Sector Perform | -- | $6 | May 21, 2025 |
| Downgrade | MYGN | Wolfe Research | Outperform | Peer Perform | -- | -- | May 8, 2025 |
| Downgrade | MYGN | Wells Fargo | Overweight | Equal Weight | -- | $6 | May 7, 2025 |
| Downgrade | MYGN | Guggenheim | Buy | Neutral | -- | -- | April 9, 2025 |
| Upgrade | MYGN | Piper Sandler | Neutral | Overweight | $11.5 | $12.5 | March 12, 2025 |
| Initiation | MYGN | Craig Hallum | -- | Buy | -- | $29 | Feb. 12, 2025 |
| Initiation | MYGN | UBS | -- | Neutral | -- | $18 | Dec. 10, 2024 |
| Downgrade | MYGN | Leerink Partners | Outperform | Market Perform | $30 | $21 | Dec. 9, 2024 |
| Initiation | MYGN | Morgan Stanley | -- | Equal Weight | -- | $32 | Sept. 19, 2024 |
| Initiation | MYGN | Wells Fargo | -- | Overweight | -- | $35 | Aug. 28, 2024 |
News
Levi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) Over Possible Securities Fraud
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.
Read More
Ongoing Myriad Genetics, Inc. (MYGN) Investigation: Protect Your Rights - Contact Levi & Korsinsky
Published: May 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.
Read More
ATTENTION MYGN Shareholders: Lost Money on Myriad Genetics, Inc.? Contact Levi & Korsinsky About Investigation
Published: May 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation
Published: May 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.
Read More
Fraud Investigation Opened: Levi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) on Behalf of Shareholders
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.
Read More
Levi & Korsinsky Investigates Possible Securities Fraud by Myriad Genetics, Inc. (MYGN)
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.
Read More
Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.
Read More
Myriad Genetics, Inc. (MYGN) Under Investigation for Potential Securities Law Violations - Contact Levi & Korsinsky Today
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.
Read More
Levi & Korsinsky Investigates Possible Securities Fraud by Myriad Genetics, Inc. (MYGN)
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.
Read More
Lost Money on Myriad Genetics, Inc. (MYGN)? Contact Levi & Korsinsky About Fraud Investigation
Published: May 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Investors to Reach Out
Published: May 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.
Read More
Ongoing Myriad Genetics, Inc. (MYGN) Investigation: Protect Your Rights - Contact Levi & Korsinsky
Published: May 15, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.
Read More
MYGN ALERT: Ongoing Investigation Into Myriad Genetics, Inc. - Contact Levi & Korsinsky
Published: May 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Connect
Published: May 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.
Read More
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Myriad Genetics, Inc. (MYGN)
Published: May 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.
Read More
Lost Money on Myriad Genetics, Inc. (MYGN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
Published: May 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.
Read More
Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Published: May 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.
Read More
Myriad Genetics, Inc. (MYGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MYRIAD GENETICS, INC. (MYGN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights b.
Read More
Down -49.47% in 4 Weeks, Here's Why Myriad (MYGN) Looks Ripe for a Turnaround
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Myriad (MYGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Read More
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON MYRIAD GENETICS, INC. (MYGN), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On May 6, 2025, Myriad released its first quarter 2025 financi.
Read More
MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Myriad Genetics delivers a narrower-than-expected loss in the first quarter of 2025.
Read More
Myriad Genetics, Inc. (MYGN) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Myriad Genetics, Inc. (NASDAQ:MYGN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Matt Scalo - SVP, IR Sam Raha - President & CEO Scott Leffler - CFO Mark Verratti - COO Conference Call Participants Doug Schenkel - Wolfe Research Puneet Souda - Leerink Partners David Westenberg - Piper Sandler Tejas Sawant - Morgan Stanley Sung Ji Nam - Scotiabank Andrew Cooper - Raymond James Tycho Peterson - Jefferies Lu Li - UBS Operator Welcome to the Myriad Genetics First Quarter 2025 Financial Earnings Conference Call. [Operator Instructions] I would now like to hand the …
Read More
Myriad (MYGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Myriad (MYGN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Myriad Genetics (MYGN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.01 per share a year ago.
Read More
Is Myriad Genetics Stock Worth Holding in Your Portfolio Now?
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Strategic progress and solid potential in oncology testing keep MYGN on investors' radar.
Read More
Medical Equipment Stock Jumps on Upgrade
Published: March 12, 2025 by: Schaeffers Research
Sentiment: Positive
Medical equipment stock Myriad Genetics Inc (NASDAQ:MYGN) was last seen up 9.8% at $11.25, after an upgrade from Piper Sandler to "overweight" from "neutral," with a price-target hike to $12.50 from $11.50.
Read More
Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO
Published: February 25, 2025 by: Benzinga
Sentiment: Negative
On Monday, in its earnings release, Myriad Genetics Inc. MYGN said Unitedhealth Group Inc's UNH UnitedHealthcare will stop covering multi-gene panel pharmacogenetic testing, including Myriad Genetics' GeneSight test, for its commercial, individual exchange, and certain managed Medicaid plans. This change takes effect in the first half of 2025.
Read More
MYGN Q4 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
Myriad Genetics achieves strong revenue growth in the fourth quarter of 2024.
Read More
Myriad (MYGN) Reports Q4 Earnings: What Key Metrics Have to Say
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
About Myriad Genetics, Inc. (MYGN)
- IPO Date 1995-10-06
- Website https://myriad.com
- Industry Medical - Diagnostics & Research
- CEO Mr. Samraat S. Raha
- Employees 2700